2SPD-008 Subgroup analysis of patients treated with trastuzumab emtansine

BACKGROUND: Trastuzumab emtansine (T-DM1) was studied in the EMILIA trial as a second line of treatment for HER-2 positive metastatic breast cancer (MBC), following the trastuzumab-taxane first-line scheme. However, the demonstration of the superiority of pertuzumab-trastuzumab-taxane as the first l...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Hosp Pharm
Päätekijät: Ortega, P Martinez, Gonzalez-Haba, E, Marzal-Alfaro, B, Garcia-Martin, E, Garcia-Moreno, F, Ortega-Navarro, C, Herranz-Alonso, A, Sanjurjo-Saez, M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Group 2018
Aiheet:
Section 2: Selection, procurement and distribution
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535383/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.29
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia